News
Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its ...
Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...
After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback